Works matching IS 01615505 AND DT 2022 AND VI 63 AND IP 2

Results: 33

FDA Approves New 68Ga Kit for Prostate Cancer PET.

Published in:: Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 26N
Publication type:: Article

DOE and HHS Certify Sufficient 99 Mo Supplies.

Published in:: Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 26N
Publication type:: Article

Letter to the Editor: "18F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study".

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.122.263837

By:

Langen, Karl-Josef;
Mottaghy, Felix M.

Publication type:

Article

Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.122.263802

By:

Privé, Bastiaan M.;
Peters, Steffie M. B.;
Uijen, Maike J. M.;
Janssen, Marcel J. R.;
van Gemert, Willemijn A. M.;
Kreissl, Michael C.;
Ezzidin, Samer;
Konijnenberg, Mark W.;
Nagarajah, James

Publication type:

Article

Reply to 'Adding non-tumor radiomic features to the prognostic model is bothersome but useful'.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263730

By:

Yusufaly, Tahir I.;
Mell, Loren K.

Publication type:

Article

The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer - Going Beneath the Surface with Molecular Imaging.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263684

By:

Sutera, Philip;
Phillips, Ryan M.;
Deek, Matthew;
Ozyigit, Gokhan;
Onal, Cem;
Tran, Phuoc T.

Publication type:

Article

Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263638

By:

Kuo, Phillip H.;
Benson, Taylor;
Messmann, Richard;
Groaning, Michael

Publication type:

Article

18F-FDG Fetal Dosimetry Calculated with PET/MRI.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263561

By:

Zanotti-Fregonara, Paolo;
Tatsuya Ishiguro;
Kosuke Yoshihara;
Shiro Ishii;
Takayuki Enomoto

Publication type:

Article

The change in management by 18F-DCFPyL PSMA PET scanning in patients undergoing post-prostatectomy radiotherapy, with early biochemical response outcomes.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263521

By:

Ng, Michael;
Guerrieri, Mario;
Lih Ming Wong;
Taubman, Kim;
Sutherland, Tom;
Benson, Angela;
Byrne, Graeme;
Koschel, Sam;
Yap, Kelvin;
Starmans, Michelle;
Ong, Grace;
Macleod, Craig;
Foo, Marcus;
Chao, Michael

Publication type:

Article

Administration Routes for SSTR- / PSMA- and FAP-directed Theranostic Radioligands in Mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263453

By:

Klose, Jasmin M.;
Wosniack, Jasmin;
Iking, Janette;
Staniszewska, Magdalena;
Zarrad, Fadi;
Trajkovic-Arsic, Marija;
Herrmann, Ken;
Costa, Pedro Fragoso;
Lueckerath, Katharina;
Fendler, Wolfgang P.

Publication type:

Article

Proceedings: PET Drugs: A Workshop on Inspections Management and Regulatory Considerations.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263443

By:

Bunning, Sue;
Ignace, Christopher;
Mattmuller, Steve;
Schwarz, Sally W.;
Scott, Peter J. H.;
VanBrocklin, Henry F.;
Zigler, Steven S.

Publication type:

Article

Analysis of short term and stable DNA damage in patients with differentiated thyroid cancer treated with 131I in hypothyroidism or with rhTSH for remnant ablation.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263442

By:

Signore, Alberto;
Campagna, Giuseppe;
Marinaccio, Jessica;
de Vitis, Marco;
Lauri, Chiara;
Berardinelli, Francesco;
Tofani, Anna;
Chianelli, Marco;
Borro, Marina;
Gentile, Giovanna;
Simmaco, Maurizio;
Colombini, Francesco;
Giovanetti, Anna;
Sgura, Antonella

Publication type:

Article

Utility of 18F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263440

By:

Langbein, Thomas;
Hui Wang;
Rauscher, Isabel;
Kroenke, Markus;
Knorr, Karina;
Wurzer, Alexander;
Schwamborn, Kristina;
Maurer, Tobias;
Horn, Thomas;
Haller, Bernhard;
Wester, Hans-Jürgen;
Eiber, Matthias

Publication type:

Article

Synthesis and Preclinical Evaluation of 177Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263371

By:

Wurzer, Alexander;
Kunert, Jan-Philip;
Fischer, Sebastian;
Felber, Veronika;
Beck, Roswitha;
de Rose, Francesco;
D'Alessandria, Calogero;
Weber, Wolfgang;
Wester, Hans-Jürgen

Publication type:

Article

Substitution of L-Trp by α-methyl-L-Trp in 177Lu-RM2 results in 177Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263323

By:

Günther, Thomas;
Deiser, Sandra;
Felber, Veronika;
Beck, Roswitha;
Wester, Hans-Jürgen

Publication type:

Article

Interrogating glioma-associated microglia/macrophage dynamics under CSF-1R therapy with multi-tracer in vivo PET/MR imaging.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263318

By:

Foray, Claudia;
Barca, Cristina;
Winkeler, Alexandra;
Wagner, Stefan;
Hermann, Sven;
Schäfers, Michael;
Grauer, Oliver M.;
Zinnhardt, Bastian;
Jacobs, Andreas H.

Publication type:

Article

Evaluation of Data-Driven Rigid Motion Correction in Clinical Brain PET Imaging.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263309

By:

Spangler-Bickell, Matthew G.;
Hurley, Samuel A.;
Pirasteh, Ali;
Perlman, Scott B.;
Deller, Timothy;
McMillan, Alan B.

Publication type:

Article

Positron emission tomography imaging of system xC¯ in immune cells for assessment of disease activity in mice and patients with inflammatory bowel disease.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263289

By:

Minjung Seo;
Yeji Kim;
Byong Duk Ye;
Sang Hyoung Park;
Seog-Young Kim;
Jin Hwa Jung;
Sung Wook Hwang;
Sun Young Chae;
Dong Yun Lee;
Sang Ju Lee;
Seung Jun Oh;
Jihun Kim;
Ji Young Kim;
Sae Jung Na;
Misung Kim;
Sang-Yeob Kim;
Koglin, Norman;
Stephens, Andrew W.;
Mi-Na Kweon;
Dae Hyuk Moon

Publication type:

Article

Assessing reactive astrogliosis with 18F-SMBT-1 across the Alzheimer's disease spectrum.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263255

By:

Villemagne, Victor L.;
Ryuichi Harada;
Doré, Vincent;
Shozo Furumoto;
Mulligan, Rachel;
Yukitsuka Kudo;
Burnham, Samantha;
Krishnadas, Natasha;
Bourgeat, Pierrick;
Ying Xia;
Laws, Simon;
Bozinovski, Svetlana;
Kun Huang;
Ikonomovic, Milos D.;
Fripp, Jürgen;
Kazuhiko Yanai;
Nobuyuki Okamura;
Rowe, Christopher C.

Publication type:

Article

First-in-human evaluation of 18F-SMBT-1, a novel 18F-labeled MAO-B PET tracer for imaging reactive astrogliosis.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263254

By:

Villemagne, Victor L.;
Harada, Ryuichi;
Doré, Vincent;
Shozo Furumoto;
Mulligan, Rachel;
Yukitsuka Kudo;
Burnham, Samantha;
Krishnadas, Natasha;
Bozinovski, Svetlana;
Kun Huang;
Lopresti, Brian J.;
Kazuhiko Yanai;
Rowe, Christopher C.;
Nobuyuki Okamura

Publication type:

Article

Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263230

By:

Delpassand, Ebrahim S.;
Tworowska, Izabela;
Esfandiari, Rouzbeh;
Torgue, Julien;
Hurt, Jason;
Shafie, Afshin;
Núñez, Rodolfo

Publication type:

Article

SV2A PET imaging is a non-invasive marker for the detection of spinal damages in experimental models of spinal cord injury.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263222

By:

Bertoglio, Daniele;
Halloin, Nicolas;
De Lombaerde, Stef;
Jankovski, Aleksandar;
Verhaeghe, Jeroen;
Nicaise, Charles;
Staelens, Steven

Publication type:

Article

Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263221

By:

Korsen, Joshua A.;
Kalidindi, Teja M.;
Khitrov, Samantha;
Samuels, Zachary V.;
Chakraborty, Goutam;
Gutierrez, Julia A.;
Poirier, John T.;
Rudin, Charles M.;
Yu Chen;
Morris, Michael J.;
Pillarsetty, Naga Vara Kishore;
Lewis, Jason S.

Publication type:

Article

18F-PFPN PET: a new and attractive imaging modality for patients with malignant melanoma.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263179

By:

Xiao Zhang;
Mengting Li;
Yongkang Gai;
Jing Chen;
Juan Tao;
Liu Yang;
Fan Hu;
Wenyu Song;
Tzu-Chen Yen;
Xiaoli Lan

Publication type:

Article

Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263177

By:

Carlsen, Esben Andreas;
Loft, Mathias;
Loft, Annika;
Berthelsen, Anne Kiil;
Langer, Seppo W.;
Knigge, Ulrich;
Kjaer, Andreas

Publication type:

Article

In vivo evaluation of six analogs of 11C-ER176 as candidate 18F-labeled radioligands for translocator protein 18 kDa (TSPO).

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263168

By:

Jae-Hoon Lee;
Siméon, Fabrice G.;
Jeih-San Liow;
Morse, Cheryl L.;
Gladding, Robert L.;
Santamaria, Jose A. Montero;
Henter, Ioline D.;
Zoghbi, Sami S.;
Pike, Victor W.;
Innis, Robert B.

Publication type:

Article

The impact of semi-automatic segmentation methods on metabolic tumor volume, intensity and dissemination radiomics in 18F-FDG PET scans of patients with classical Hodgkin lymphoma.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263067

By:

Driessen, Julia;
Zwezerijnen, Gerben J. C.;
Schöder, Heiko;
Drees, Esther E. E.;
Kersten, Marie José;
Moskowitz, Alison J.;
Moskowitz, Craig H.;
Eertink, Jakoba J.;
de Vet, Henrica C. W.;
Hoekstra, Otto S.;
Zijlstra, Josée M.;
Boellaard, Ronald

Publication type:

Article

Short-term colony stimulating factor-1 receptor inhibition-induced repopulation after stroke assessed by longitudinal 18F-DPA-714 PET imaging.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263004

By:

Barca, Cristina;
Kiliaan, Amanda J.;
Wachsmuth, Lydia;
Foray, Claudia;
Hermann, Sven;
Faber, Cornelius;
Schäfers, Michael;
Wiesmann, Maximilian;
Zinnhardt, Bastian;
Jacobs, Andreas H.

Publication type:

Article

Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262884

By:

Alberge, Jean-Baptiste;
Kraeber-Bodéré, Françoise;
Jamet, Bastien;
Touzeau, Cyrille;
Caillon, Hélène;
Wuilleme, Soraya;
Béné, Marie-Christine;
Kampfenkel, Tobias;
Sonneveld, Pieter;
van Duin, Mark;
Avet-Loiseau, Herve;
Corre, Jill;
Magrangeas, Florence;
Carlier, Thomas;
Bodet-Milin, Caroline;
Chérel, Michel;
Moreau, Philippe;
Minvielle, Stéphane;
Bailly, Clément

Publication type:

Article

SIR-Spheres® activity measurements reveal systematic miscalibration.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262650

By:

Graves, Stephen A.;
Martin, Molly;
Tiwari, Ashok;
Merrick, Michael;
Sunderland, John

Publication type:

Article

Towards a better understanding of immune checkpoint inhibitor radiolabeled PET imaging studies.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262622

By:

Westdorp, Harm;
Verhoeff, Sarah R.;
Gotthardt, Martin;
van Herpen, Carla M. L.;
van den Heuvel, Michel M.;
Heskamp, Sandra;
Aarntzen, Erik H. J. G.

Publication type:

Article

Fluorescent molecular imaging can improve intraoperative sentinel margin detection in oral squamous cell carcinoma.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262235

By:

Krishnan, Giri;
van den Berg, Nynke S.;
Naoki Nishio;
Kapoor, Shrey;
Pei, Jaqueline;
Freeman, Laura;
Yu-Jin Lee;
van Keulen, Stan;
Farkurnejad, Shayan;
Condon, James;
Baik, Fred M.;
Martin, Brock A.;
Rosenthal, Eben L.

Publication type:

Article

CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262485

By:

Farwell, Michael D.;
Gamache, Raymond F.;
Babazada, Hasan;
Hellmann, Matthew D.;
Harding, James J.;
Korn, Ron;
Mascioni, Alessandro;
Le, William;
Wilson, Ian;
Gordon, Michael S.;
Wu, Anna M.;
Ulaner, Gary A.;
Wolchok, Jedd D.;
Postow, Michael A.;
Pandit-Taskar, Neeta

Publication type:

Article

Works matching IS 01615505 AND DT 2022 AND VI 63 AND IP 2

FDA Approves New<sup> 68</sup>Ga Kit for Prostate Cancer PET.

DOE and HHS Certify Sufficient <sup>99</sup> Mo Supplies.

Letter to the Editor: "<sup>18</sup>F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study".

Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?

Reply to 'Adding non-tumor radiomic features to the prognostic model is bothersome but useful'.

The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer - Going Beneath the Surface with Molecular Imaging.

Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial.

<sup>18</sup>F-FDG Fetal Dosimetry Calculated with PET/MRI.

The change in management by <sup>18</sup>F-DCFPyL PSMA PET scanning in patients undergoing post-prostatectomy radiotherapy, with early biochemical response outcomes.

Administration Routes for SSTR- / PSMA- and FAP-directed Theranostic Radioligands in Mice.

Proceedings: PET Drugs: A Workshop on Inspections Management and Regulatory Considerations.

Analysis of short term and stable DNA damage in patients with differentiated thyroid cancer treated with <sup>131</sup>I in hypothyroidism or with rhTSH for remnant ablation.

Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.

Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.

Substitution of L-Trp by α-methyl-L-Trp in <sup>177</sup>Lu-RM2 results in <sup>177</sup>Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability.

Interrogating glioma-associated microglia/macrophage dynamics under CSF-1R therapy with multi-tracer in vivo PET/MR imaging.

Evaluation of Data-Driven Rigid Motion Correction in Clinical Brain PET Imaging.

Positron emission tomography imaging of system xC¯ in immune cells for assessment of disease activity in mice and patients with inflammatory bowel disease.

Assessing reactive astrogliosis with <sup>18</sup>F-SMBT-1 across the Alzheimer's disease spectrum.

First-in-human evaluation of <sup>18</sup>F-SMBT-1, a novel <sup>18</sup>F-labeled MAO-B PET tracer for imaging reactive astrogliosis.

Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

SV2A PET imaging is a non-invasive marker for the detection of spinal damages in experimental models of spinal cord injury.

Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3.

<sup>18</sup>F-PFPN PET: a new and attractive imaging modality for patients with malignant melanoma.

Prospective phase II trial of prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.

In vivo evaluation of six analogs of <sup>11</sup>C-ER176 as candidate <sup>18</sup>F-labeled radioligands for translocator protein 18 kDa (TSPO).

The impact of semi-automatic segmentation methods on metabolic tumor volume, intensity and dissemination radiomics in <sup>18</sup>F-FDG PET scans of patients with classical Hodgkin lymphoma.

Short-term colony stimulating factor-1 receptor inhibition-induced repopulation after stroke assessed by longitudinal 18F-DPA-714 PET imaging.

Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.

SIR-Spheres® activity measurements reveal systematic miscalibration.

Towards a better understanding of immune checkpoint inhibitor radiolabeled PET imaging studies.

Fluorescent molecular imaging can improve intraoperative sentinel margin detection in oral squamous cell carcinoma.

CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.